Arc 13Smartwatches and Neural Regeneration
Wei Kang’s ECG technology became the foundation for major smartwatch partnerships and life-saving devices, while Sanqing advanced a neural regeneration drug toward clinical trials. The arc ended with pharmaceutical executives abandoning their own research after learning that Three Purities had already developed a drug.
- Wei Kang patented the Portable Monitoring Module and formed a medical devices division, where Lu Tingfeng’s heart attack demonstrated the fitness band’s early-warning value.
- Sanqing’s wristband and Longtu APP attracted Huawei, Rice, OPPO, VIVO, and Apple, though Apple struggled to match the module’s readings and could not access Sanqing’s diagnostic algorithm.
- Huawei launched smartwatches using Sanqing’s technology, and rescue stories from a subway platform and an Everest expedition helped drive broad public interest and sales.
- Wei Kang agreed to work with the Aerospace Center on a portable astronaut health-monitoring device, while Apple and Samsung sought Sanqing’s ECG technology and were rebuffed.
- Chen Yiqing reported that Sanqing had developed a drug activating dormant neural stem cells, and Wei Kang approved publication and further research.
- Wei Kang approved Wenren Long’s HIV treatment plan, which used CCR5 antagonists while also having him assist Tang Que’s gene-editing work.
- Chen Yiqing’s brain neuron regeneration paper appeared as a Cell cover article, and researchers worldwide replicated his results while Sanqing’s Neural Regeneration Factor entered Phase I trials in China.
- Davis gathered pharmaceutical executives after learning of Sanqing’s clinical trial, but they said their own research had failed and abandoned the field.